Access the full text.
Sign up today, get DeepDyve free for 14 days.
U. Tunn, G. Canepa, A. Kochanowsky, E. Kienle (2012)
Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapyProstate Cancer and Prostatic Diseases, 15
J Kawakami, JE Cowan, EP Elkin (2006)
Androgen-deprivation therapy as primary treatment for localized prostate cancer: Data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), 106
M. Maio, F. Perrone, P. Conte (2019)
Real-World Evidence in Oncology: Opportunities and Limitations.The oncologist
D. Spiegel, Julian Hong, T. Oyekunle, L. Waters, W. Lee, J. Salama, B. Koontz (2019)
A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.International journal of radiation oncology, biology, physics, 103 4
S. Brawley, R. Mohan, Christopher Nein (2018)
Localized Prostate Cancer: Treatment Options.American family physician, 97 12
R. Siegel, K. Miller, Hannah Fuchs, A. Jemal (2021)
Cancer Statistics, 2021CA: A Cancer Journal for Clinicians, 71
Daniel Yang, J. Miccio, V. Jairam, E. Chang, Jun Yu, Henry Park, S. Aneja (2020)
The Impact of Missing/Incomplete Data in Real-World Data StudiesInternational Journal of Radiation Oncology Biology Physics, 108
H. Ahmadi, S. Daneshmand (2013)
Androgen deprivation therapy: evidence‐based management of side effectsBJU International, 111
A. Chowdhry, V. Gondi, S. Pugh (2021)
Missing Data in Clinical Studies.International journal of radiation oncology, biology, physics
Jianlin Shi, John Hurdle (2018)
Trie-based rule processing for clinical NLP: A use-case study of n-trie, making the ConText algorithm more efficient and scalableJournal of biomedical informatics, 85
M. Grossmann, A. Cheung, J. Zajac (2013)
Androgens and prostate cancer; pathogenesis and deprivation therapy.Best practice & research. Clinical endocrinology & metabolism, 27 4
Jun Kawakami, J. Cowan, E. Elkin, D. Latini, J. Duchane, P. Carroll (2006)
Androgen‐deprivation therapy as primary treatment for localized prostate cancerCancer, 106
B. Nascimento, E. Miranda, L. Jenkins, N. Benfante, E. Schofield, J. Mulhall (2019)
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.The journal of sexual medicine, 16 6
M. Perlmutter, H. Lepor (2007)
Androgen deprivation therapy in the treatment of advanced prostate cancer.Reviews in urology, 9 Suppl 1
W. Nam, Se Choi, S. Yoo, J. Ryu, Jaehoon Lee, Y. Kyung, Jae Han, D. You, I. Jeong, J. Hong, H. Ahn, Choung-Soo Kim (2017)
Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancerInvestigative and Clinical Urology, 59
V. Rudrapatna, A. Butte (2020)
Opportunities and challenges in using real-world data for health care.The Journal of clinical investigation, 130 2
M. Tanenblatt, A. Coden, I. Sominsky (2010)
The ConceptMapper Approach to Named Entity Recognition
PURPOSEData quality and standardization remain a challenge when analyzing real-world clinical data. We built a clinical research database, using machine learning and natural learning processing, and investigated factors influencing testosterone recovery (T-recovery) in patients with localized prostate cancer (LPC) after initial androgen deprivation therapy (ADT).METHODSMedication and treatment-associated dates missing in structured tables were extracted from patient notes using ConceptMapper, an automated data extraction tool, standardized and curated in Sema4 clinical research database. ADT usage duration was evaluated, and T-recovery in patients with LPC was analyzed by the Kaplan-Meier method and multivariable Cox proportional hazards models. We assessed the prognostic value of post-ADT T-recovery with prostate-specific antigen progression-free survival and failure-free survival.RESULTSIn total, 4,125 of 30,832 (13.4%) patients with prostate cancer had medication exclusively from notes with high precision and recall, F1 score ≥ 0.95. Association of dates with medication usage had a F1 score of 0.76. ADT duration estimation had higher accuracy combining information from notes to tables from electronic medical record (70% v 45%). Baseline testosterone was the strongest predictor of T-recovery in these patients. Patients with a baseline testosterone ≥ 300 ng/dL recovered in 9.79 versus 38 months for patients with baseline testosterone < 300 ng/dL (P < .0001). Shorter prostate-specific antigen progression-free interval was observed for patients with T-recovery (≥ 300 ng/dL) at 6 months after ADT cessation compared with patients without T-recovery (< 300 ng/dL; 13.7 v 25.1 months; P = .055).CONCLUSIONWe augmented structured electronic medical record data with data extracted from notes and improved the accuracy of medication information for patients. ADT exposure and T-recovery in patients with LPC produced results consistent with the literature and clinical experience and illustrates the power of applying machine learning methods to enhance the quality of real-world evidence in answering clinically relevant questions.
JCO: Clinical Cancer Informatics – Wolters Kluwer Health
Published: Jun 13, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.